HomeAI · summaries
Storia in 2 fonti
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead asset TRIV-509 expected by year-end.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive…
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
- ·
endpoints.news
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
Triveni Bio closes a $65M Series C to fund two eczema drug candidates targeting kallikreins and IL-13, with Phase 2a data on lead asset TRIV-509 expected by year-end.